Verve TherapeuticsVERV
About: Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
Employees: 274
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
213% more call options, than puts
Call options by funds: $1.09M | Put options by funds: $348K
163% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 16
15% more funds holding
Funds holding: 166 [Q4 2024] → 191 (+25) [Q1 2025]
1.99% less ownership
Funds ownership: 92.92% [Q4 2024] → 90.92% (-1.99%) [Q1 2025]
16% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 64
17% less capital invested
Capital invested by funds: $444M [Q4 2024] → $369M (-$74.7M) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Guggenheim Etzer Darout | 290%upside $24 | Buy Maintained | 15 Apr 2025 |
Canaccord Genuity Whitney Ijem | 533%upside $39 | Buy Maintained | 15 Apr 2025 |
HC Wainwright & Co. Mitchell Kapoor | 306%upside $25 | Buy Maintained | 14 Apr 2025 |
Financial journalist opinion
Based on 7 articles about VERV published over the past 30 days
